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Abstract
Background: Neutropenia is a common toxicity in chemotherapy but detailed information about
how neutropenia is associated with changes in patients' quality of life is not readily available. This
prospective study interviewed patients with grade 4 neutropenia to provide qualitative information
on patients' experience of developing and coping with grade 4 neutropenia during a cycle of
chemotherapy.
Methods: A sample of 34 patients who developed grade 4 neutropenia during the first cycle of
chemotherapy completed a total of 100 structured clinical interviews. Interviews were transcribed,
and 2 raters inductively developed 5 broad categories comprising 80 specific complaint domains
nominated by patients. Thirty-five patient-nominated problems were mentioned in 5% or more of
the interviews.
Results: Fatigue was the most common physical symptom. Interference in daily routine, negative
self-evaluation, negative emotion, and social isolation were other common complaints associated
with neutropenia.
Conclusion: Neutropenia is associated with a number of negative experiences among cancer
patients undergoing chemotherapy, and these negative experiences have an adverse effect on the
patient's quality of life. Oncology nurses can play a key role in helping patients manage adverse
effects to maintain their quality of life.
Background
Quality of life (QOL) issues have historically played an
important part in the nursing role of patient advocacy.
Ropka et al. found in the Year 2000 ONS Research Priori-
ties Survey that quality of life ranked second among the
top 20 research priorities of sampled nurses [1]. Other pri-
orities included neutropenia/immunosuppression (fifth),
as well as depression and stress-coping adaptation in thir-
teenth and fourteenth place respectively. These research
priorities and the realization that accurate assessment of
QOL in patients can provide both physicians and nurses
with important clinical information [2] have provided the
framework for initiating this research on the correlation
between chemotherapy-induced neutropenia and QOL.
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The term quality of life has been defined and measured in
many different ways in the literature. Haas [3] offers the
following definition to differentiate QOL from closely
related concepts such as well-being, satisfaction with life,
and functional status:
"QOL is a multidimensional evaluation of an individual's
current life circumstances in the context of the culture and
value systems in which they live and the values they hold.
QOL is primarily a subjective sense of well-being encom-
passing physical, psychological, social and spiritual
dimensions..."
Complications and side effects of cancer treatment can
not only adversely affect clinical outcomes, but also nega-
tive influence a patient's quality of life. Chemotherapy
specifically can impact the patient's QOL by significantly
impacting social, physical and global functionality [4].
Many cancer chemotherapies work by suppressing fast-
dividing cells like cancer cells; however, the fast-dividing
cells of the bone marrow, which are responsible for pro-
ducing the cells involved in the first line immune defense
such as neutrophils and other white cells, can also be neg-
atively affected. Neutropenia, i.e., decreased white blood
cell counts, is the name given to this side effect of such
myelosuppressive chemotherapies. The National Cancer
Institute's Common Toxicity Criteria provides for 5 grades
of neutropenia (Grade 5 = death) [5]. Grade 4 neutrope-
nia is defined by an absolute neutrophil count (ANC) of
less than 0.5 × 109 cells/L, commonly referred to as an
ANC of less than 500 cells/mL. By comparison, grade 0,
which is considered a normal count, varies from 3 to 6 ×
109 cells/L. When patients develop febrile neutropenia
(grade 4 neutropenia plus fever [i.e., a body temperature
of greater than 38.5°C), they are often hospitalized and
placed on antibiotics to prevent life-threatening sepsis
[6,7]. In addition to the clinical consequences of febrile
neutropenia, hospitalization and possible isolation can
have a significant impact on a patient's quality of life.
Little is actually known about the impact of neutropenia
on quality of life, which has only occasionally been exam-
ined as a secondary outcome in the context of side effects
of chemotherapies. Fortner [8] reported on a cohort of 62
patients receiving chemotherapy with no growth factors.
Patients completed different scales (SF-36, Cancer Care
Monitor, Psychosocial Adjustment to Illness Scale (PAIS))
at weekly intervals before having their absolute neu-
trophil count (ANC) measured. The results of this study
provided preliminary evidence of the association between
CIN and QOL impairments.
Oncology nurses are increasingly playing a major role in
the management of neutropenia. Recent nursing publica-
tions have reported on the suitability of the nurse, as a
direct caregiver, to assess patients' potential risk factors for
neutropenia and implement guidelines for management
[9,10]. Maxwell et al [11] showed how the utilization
guidelines for neutropenia management could not only
save nursing staff considerable time, but also improve the
overall flow of patient care for clinical practices. An
increased knowledge of how CIN affects QOL would
assist nurses in their patient education efforts and allow
them to direct patients' preventative care measures during
myelosuppressive chemotherapy regimens.
The purpose of this preliminary investigation was to
obtain detailed information from patients, describing the
experience of becoming neutropenic. In particular, by
conducting qualitative interviews during neutropenic
periods, patients were assessed on the impact it had on
their quality of life and their routine functioning. Whereas
we value and have, in fact, deployed standardized, quan-
titative measures of quality of life, this report focuses on
qualitative information. Such qualitative information is
often obtained to assist in the development of more
finely-tuned, quantitative measures of a given condition.
The pilot study reported here has resulted in a prospective
study, results of which are going to be reported in the near
future.
Methods
Design and participants
A convenience sample of adult cancer patients with grade
4 neutropenia was evaluated in the pilot study to deter-
mine the impact of neutropenia on patient psychological
adjustment and functioning. The prospective design
restricted participation to adult cancer patients from the
West Clinic (Memphis, Tennessee) who were scheduled to
receive the first cycle of one of the following chemother-
apy regimens, at the full dose, given in either a 21- to 28-
day cycle: (1) docetaxel, (2) AT (doxorubicin and paclit-
axel), (3) CHOP (cyclophosphamide, doxorubicin, vinc-
ristine, and prednisone), (4) ESHAP (etoposide,
methylprednisolone, cisplatin, and cytarabine), (5) car-
boplatin-paclitaxel, (6) carboplatin-docetaxel, and (7)
carboplatin-gemcitabine. These chemotherapies were
selected because they were judged to be among those that
carried a significant risk of producing grade 4 neutropenia
[7,12-15]. There was no restriction on cancer type.
Patients were excluded if they were already participating
in another formal clinical trial; were scheduled to receive
supportive treatment with colony-stimulating factors (eg,
filgrastim or sargramostim); or had a life expectancy less
than three months.
Patients visited the clinic on days 0, 7, 14, and 21 of the
chemotherapy cycle for assessment of vital signs, com-
plete blood count (CBC) with differential, and QOLBMC Nursing 2005, 4:4 http://www.biomedcentral.com/1472-6955/4/4
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assessment. For this analysis, 34 patients who developed
grade 4 neutropenia (ANC < 0.5 × 109/L) at any point dur-
ing their first cycle of chemotherapy were interviewed and
completed a total of 100 interviews. Demographic and
medical characteristics of the 34 participants are shown in
Tables 1 and 2. Seventy percent or more were white, mar-
ried women who had high school or greater level of edu-
cation. Consistent with first cycle treatment in an
outpatient setting, most participants had a good (0 to 1)
Eastern Collaborative Oncology Group (ECOG) perform-
ance rating [16]. Over two thirds of patients received
docetaxel, and nearly half of the patients had either breast
cancer or lung cancer. Only 5 of the 34 patients that were
interviewed exhibited a significant fever (≥ 101.4°F) that
required hospitalization.
Procedure
Participants completed informed consent procedures
approved by Western Institutional Review Board (Olym-
pia, Washington). Participants were compensated for
their participation.
Interview schedule
Participants were scheduled to be interviewed on days 7,
10, 14, and 21 of their respective chemotherapy cycle, but
the interviews only began once a patient had an ANC < 0.5
× 109/L (grade 4). Nursing staff in consultation with treat-
ing physicians examined the laboratory results and con-
tacted research staff to come and interview the patient. For
example, a patient who first developed grade 2 neutrope-
nia on day 7 and grade 4 neutropenia on day 10 would
have contributed only 3 interviews (days 10, 14, and 21).
Thirty-three of the 34 patients who developed grade 4
neutropenia did so on or before day 10 of chemotherapy;
one patient who was receiving carboplatin-gemcitabine
chemotherapy first developed grade 4 neutropenia on day
21.
Interview protocol
The interviews were conducted by trained interviewers
during clinic visits. Interviewers were 4 advanced graduate
students in clinical psychology who were highly trained
and experienced in structured clinical interviewing tech-
niques with special emphasis on employing empathic
reflection, asking open-ended questions, and using tech-
niques to promote patient elaboration of their own expe-
riences. These interviewers were part of the clinics staff in
clinical research assistant positions.
The interview protocol was designed to obtain the partic-
ipant's perspective of the impact of neutropenia within
the context of an empathic conversation. Although not
administered in this study, the interviewers had also been
trained in the Structured Clinical Interview to Diagnose
DSM-IV Axis I Disorders (SCID) and were familiar with
the criteria needed to identify individuals who might need
special assistance and referral for severe psychiatric diffi-
culties [17].
Medical staff (either physicians or nurses) informed par-
ticipants of their current ANC and, if appropriate,
explained that the condition was called neutropenia.
Patients were instructed in how to keep a diary of symp-
toms and how to monitor temperature with a thermome-
ter that was provided for home use. Patients were then
interviewed by the clinical assistant. Interviews lasted 20
Table 1: Demographic Characteristics
Number of Patients with Grade 4 Neutropenia 34
Mean age in years (range) 61.4 (27 – 76)
Women 71%
Ethnic background
Black/African American 18%
White/not Hispanic 82%
Education ≥ 12 years 76%
Marital status
Married 70%
Single 6%
Divorced 3%
Widowed 21%
Family income ($)
Under 14,600 11%
14,601 to 29,999 19%
30,000 to 49,999 18%
50,000 to 79,999 29%
80,000 to 99,999 15%
100,000 to 220,000 8%
Table 2: Medical Characteristics of 34 Adult Cancer Patients 
with Grade 4 Neutropenia
Good ECOG performance statusa 79%
Cancer diagnosis
Breast 28%
Lung 24%
Lymphoma 15%
Ovarian 9%
Prostate 6%
Other diagnoses 18%
Metastatic disease 37%
Type of chemotherapy
Docetaxel 70%
CHOP 12%
Carboplatin-docetaxel 15%
Carboplatin-gemcitabine 3%
Hospitalization due to neutropenia and grade 3 fever 15%
a Good performance status is defined as ECOG performance scale 
score of 0 to 1 on a 5-point scale, where 0 is fully active, and 4 is 
completely disabled [13].BMC Nursing 2005, 4:4 http://www.biomedcentral.com/1472-6955/4/4
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minutes and were retrospective accounts of the impact of
neutropenia covering the period between the interview
and the preceding visit. The following topics were cov-
ered, and all were phrased in terms of changes since the
previous visit: physical feelings and sensations, reduction
and/or cessation of activities, interactions with others,
financial impacts, ability to work, sex life, emotions, satis-
faction with medical care, thoughts about disease,
thoughts about treatment procedures, and overall quality
of life. These areas were covered because they represent
aspects of quality of life that might be affected by grade 4
neutropenia. In addition, interviewers encouraged partic-
ipants to talk freely and to describe in their own words
how they were feeling and how their daily living had been
different after developing neutropenia. Every interview
was recorded and transcribed verbatim.
Preliminary analyses
Two raters characterized the information in the interviews
by reviewing all transcripts and inductively developing
descriptive categories for the nature of patient concerns
expressed in the transcript [18-20]. Raters resolved dis-
crepancies by mutual agreement. This procedure yielded
80 unique, descriptive problem domains, distributed over
5 broad categories as follows: Physical Complaints (n =
29), Daily Routine Disruptions (n = 14), Negative
Thought and Self Evaluation (n = 17), Negative Emotions
(n = 10), and Social Relationships (n = 10). Two raters
then counted the instances of each problem domain
within the 100 interview transcripts, and any discrepan-
cies were resolved by mutual agreement. Table 3 illus-
trates the 5 broad categories along with selected unique
problem domains and an illustrative exemplar for the
displayed problem domain.
Results
Tables 4 through 8 illustrate the results of the tabulations
of only the unique problem domains that were nomi-
nated in 5% or more of the interview. This restriction per-
mitted a balance between rich description and
characteristic or representative patient reactions to grade 4
neutropenia. These tables are designed to show how often
a given problem was mentioned within the 100 interviews
and also how frequently an individual patient mentioned
the given problem, and data are presented in order of
descending frequency. Altogether, the tables present infor-
mation about 35 of the 80 specific problem domains
identified in the content analysis of the interview
transcripts.
Table 4 shows the frequency of the occurrence of patient-
nominated problem domains broadly categorized as
physical complaints. The most frequent problem men-
tioned by these patients with grade 4 neutropenia was
fatigue, which was expressed using terms such as feeling
tired, weak, and drained. Fully 91% of the participants
complained about fatigue and its interference with their
daily lives. In terms of frequency in the interviews, no
other physical complaint matched fatigue, which was a
complaint in nearly 70% of the interviews compared with
less than 20% for other problems across interviews. Sleep
interruption, muscle aches, pain, and sore throat were the
next most frequently mentioned physical complaints, and
these affected between 41% and 14% of the patients inter-
Table 3: Categories and Exemplars of Patient-nominated Effects of Neutropenia
Major Category Specific Problem Domain Illustrative Exemplars in Patients' Own Words
Physical Complaints
Tired, fatigued, exhausted, weak, feeling "drained" If I walk from one room to the next, I'm worn out.
Reduced sexual activity It has definitely slowed down. I don't have a great deal of interest.
Daily Routine Disruptions
Loss of daily routine I have stopped going to church and taking my son to school.
Difficulties with household activities I have stopped most everything. I am not doing my housework.
Negative Thought and Self Evaluation
Worrying about paying for extra care needed If I don't work, I don't get paid. It's getting very scary.
Feeling useless/helpless, letting people down I feel guilty when I see other people doing work I should be doing.
Negative Emotions
Feeling down I feel like giving up. I just wish it would all end.
Feeling anxious I am scared. I hope I don't have to go through this (neutropenia) the next three times I 
come here.
Social Relationships
Decreased social contacts and activity I can't spend time with other people because I am sick.
Avoiding crowds I don't go to church because someone might hug me or sneeze near me.
Note: This table contains selected exemplars of the problem domains presented by patients in the five broad categories identified as follows: 
Physical Complaints, Daily Routine Disruptions, Negative Thought and Self Evaluation, Negative Emotions, and Social Relationships.BMC Nursing 2005, 4:4 http://www.biomedcentral.com/1472-6955/4/4
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viewed. With the exception of skin irritations, which
affected 9% of the patients, the remaining problems listed
in Table 4 affected between 15% and 21% of the
participants.
It should be noted that, in part because of the nature of
the data, while we have an association between grade 4
neutropenia and these complaints, we do not have a
causal link. It is entirely likely that some of these com-
plaints such as fatigue and exhaustion are endemic to
chemotherapy and would occur at a comparable rate
among similar patients with similar cancers undergoing
the same chemotherapy, only without the condition of
grade 4 neutropenia. Given what little is known about the
experience of neutropenia from the patient's perspective,
this may be a reasonable start to finding out how the phys-
ical impact of neutropenia affects patient functioning and
quality of life. The top five complaints listed in Table 4
certainly could be complaints that are exacerbated, if not
caused, by neutropenia.
Table 5 lists the most frequently mentioned effects of neu-
tropenia on patients' daily routine. Over half of the
patients noted that their daily routine was interrupted,
preventing them from leading normal lives. This effect
was especially noted in terms of physical activity and may
simply be a correlate of the severe fatigue that nearly all of
the patients reported. In terms of quality of life, this inter-
ference with the activities of daily living prevented these
neutropenic patients from engaging in the physical and
social activities that brought them pleasure and made life
enjoyable.
Table 4: Patient-nominated Physical Complaints During and After Grade 4 Episodes of Chemotherapy-induced Neutropenia
Patient-nominated Physical Complaint Frequency Per Interview 
(N = 100) n (%)
Frequency Per Patient 
(N = 34) n (%)
Tired, fatigued, exhausted, weak, feeling "drained" 69 (69%) 31 (91%)
Sleep interruption (eg, onset insomnia, waking) 19 (19%) 14 (41%)
Muscle aches, feeling achy, swollen joints 16 (16%) 13 (38%)
Pain 15 (15%) 10 (29%)
Cough, sore throat, mucous in throat, problems swallowing 10 (10%) 8 (24%)
Reduced sexual activity (eg, too tired for sex) 9 (9%) 6 (18%)
Change in taste of foods 7 (7%) 6 (18%)
Decreased appetite 7 (7%) 7 (21%)
Diarrhea 7 (7%) 6 (18%)
Stomach upset, cramping 7 (7%) 7 (21%)
Mouth Sores 6 (6%) 6 (18%)
Nausea 5 (5%) 5 (15%)
Skin problems (rash, skin breaking out, dry skin) 5 (5%) 3 (9%)
Note: Thirty-four patients completed 100 interviews with each patient contributing between 1 and 4 interviews. To be included in the table, the 
complaint had to have been nominated within at least 5% of the interviews.
Table 5: Patient-nominated Daily Routine Disruption Problems During and After Grade 4 Episodes of Chemotherapy-induced 
Neutropenia
Patient-nominated Daily Routine Disruption Problems Frequency Per Interview 
(N = 100) n (%)
Frequency Per Patient 
(N = 34) n (%)
Loss of daily routine ("Cannot live life like I used to") 42 (42%) 19 (56%)
Unable to engage in normal physical activities 39 (39%) 19 (56%)
Difficulties with household activities (eg cooking) 34 (34%) 19 (56%)
Unable to work like before 27 (27%) 13 (38%)
Laying around more and napping 25 (22%) 18 (53%)
Unable to engage in normal non-physical hobbies 23 (23%) 16 (47%)
Unable to attend religious services 21 (21%) 12 (35%)
Difficulties with childcare 9 (9%) 6 (18 %)
Note: Thirty-four patients completed 100 interviews with each patient contributing between 1 and 4 interviews. To be included in the table, the 
complaint had to have been nominated within at least 5% of the interviews.BMC Nursing 2005, 4:4 http://www.biomedcentral.com/1472-6955/4/4
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Table 6 covers the broad category of negative thinking and
negative self-evaluation. The experience of becoming neu-
tropenic was associated with a sense of dread and
increased fear about continuing further chemotherapy
treatment for nearly one fourth of these patients. Inter-
viewers were struck by the fact that some patients seemed
to begin to question their own self worth as they became
increasingly isolated and restricted because of lack of
energy and the necessary medical prohibitions to avoid
social contact during the period of high risk for infection
(ie, severe neutropenia), even though this type of com-
plaint was less frequent than physical complaints like
fatigue. This negative self-evaluation was evident in
approximately 1 out of 5 patients who developed grade 4
neutropenia.
Table 7 details the most frequent negative emotions men-
tioned during interviews. Not surprisingly, nearly one
fourth of the patients complained that they felt down or
blue. This may be a natural consequence of the fact that
over half of all the participants reported a restriction in
their daily activities that brought them pleasure and a
sense of accomplishment. A bit more surprising was the
fact that over 20% of participants reported feeling more
irritable and short tempered after episodes of
neutropenia.
Table 6: Patient-nominated Negative Thought and Self Evaluation Changes During and After Grade 4 Episodes of Chemotherapy-
induced Neutropenia
Patient-nominated Negative Thought and Self Evaluation Changes Frequency Per Interview 
(N = 100) n (%)
Frequency Per Patient 
(N = 34) n (%)
Feeling of dread about coming for chemotherapy 10 (10%) 9 (27%)
Worrying about paying for extra care needed 9 (9%) 5 (15%)
Feeling useless/helpless, letting people down 7 (7%) 6 (18%)
Sense of loss of independence 6 (6%) 5 (15%)
Worrying about being around other sick people 5 (5%) 5 (15%)
Note: Thirty-four patients completed 100 interviews with each patient contributing between 1 and 4 interviews. To be included in the table, the 
complaint had to have been nominated within at least 5% of the interviews.
Table 7: Patient-nominated Negative Emotions During and After Grade 4 Episodes of Chemotherapy-induced Neutropenia
Patient-nominated Negative Emotions Frequency Per Interview 
(N = 100) n (%)
Frequency Per Patient 
(N = 34) n (%)
Feeling down 21 (21%) 8 (24%)
Feeling irritable and frustrated 12 (12%) 7 (21%)
Crying more than usual 5 (5%) 4 (12%)
Feeling anxious 5 (5%) 5 (15%)
Note: Thirty-four patients completed 100 interviews with each patient contributing between 1 and 4 interviews. To be included in the table, the 
complaint had to have been nominated within at least 5% of the interviews.
Table 8: Patient-nominated Social Relationship Changes During and After Grade 4 Episodes of Chemotherapy-induced Neutropenia
Patient-nominated Social Relationship Changes Frequency Per Interview
 (N = 100) n (%)
Frequency Per Patient 
(N = 34) n (%)
Decreased social contacts and activity 38 (38%) 20 (59%)
Avoiding crowds 17 (17%) 11 (32%)
Other people getting on my nerves 10 (10%) 8 (24%)
Feeling lonely and isolated 6 (6%) 6 (18%)
Withdrawing and keeping to myself 6 (6%) 4 (12%)
Note: Thirty-four patients completed 100 interviews with each patient contributing between 1 and 4 interviews. To be included in the table, the 
complaint had to have been nominated within at least 5% of the interviews.BMC Nursing 2005, 4:4 http://www.biomedcentral.com/1472-6955/4/4
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Table 8 illustrates social relationship changes associated
with grade 4 neutropenia. Most patients (59%) reported a
decrease in social contacts and social outings. This most
likely resulted from the combination of the reported
severe fatigue and the doctors' orders to refrain from
social contact during the period of high infection risk.
This experience of being isolated from customary social
contacts and activities was uniformly experienced as a
negative aspect of neutropenia.
Conclusion
The picture of neutropenia that emerges from these struc-
tured clinical interviews with grade 4 neutropenic cancer
patients undergoing chemotherapy illustrates their dimin-
ished quality of life, wherein fatigue, negative emotion,
and a sense of isolation and reduced self worth are fea-
tured. To be sure, not every patient studied experienced
the full spectrum of these problems, and, even among
those who did, the intensity of the experience varied from
mild to rather severe, especially for the 5 individuals who
were hospitalized with fever. Although neutropenia is
characterized by the lab value ANC, neutropenia clearly
has a broader consequence, considering how it can impact
the quality of life of the affected patient and potentially
endanger life. Results from these interviews may be useful
in constructing measures of quality of life outcomes in
chemotherapy patients who develop neutropenia. Physi-
cal symptoms are clearly important for any such measure,
and inclusion of some measure of fatigue or exhaustion is
mandatory. As one might expect from compromised
immune functioning, patients mentioned some obvious
physical symptoms such as sore throat, mouth sores, and
swollen joints. Less intuitively obvious, but nevertheless
important, were other symptoms such as sleep interrup-
tion and reduced sexual activity. These suggest that even
the physical symptoms associated with neutropenia are
not as straightforward as one might expect. The impact of
neutropenia goes beyond physical symptoms to affect
social, cognitive, and emotional functioning of patients.
We found that most patients reported significant disrup-
tions to their daily routine. The degree to which their
fatigue and exhaustion interfered with their ability to live
a normal life was striking. Instead of being able to carry on
as before, these patients reported that they were upset and
often felt guilty about not being able to do those routine
tasks that gave them a sense of personal fulfillment and
pleasure. Being in this debilitated state and unable to carry
on with their usual routines also led to negative self-
appraisals and negative emotions. It should be noted that
we do not regard these reactions to be unusual or out of
the ordinary. In fact, we consider these reactions to be nor-
mal, considering the very difficult physical conditions of
undergoing chemotherapy with the added burden of
developing neutropenia and the fact that we did not
observe psychiatric disorders among these patients.
Continued research is needed to establish specific correla-
tions between physical symptoms caused by neutropenia
and their psychosocial effects. This will further assist
nurses and physicians to understand the impact of neutro-
penia on patients and allow them to institute specific
interventions to decrease the severity of side effects from
myelosuppresive chemotherapy as well as to ameliorate
their influence on the patients' quality of life. As a quali-
tative and preliminary study of the quality of life
implications of neutropenia, this investigation has some
important limitations. We focused on those patients who
became neutropenic as defined by grade 4 neutropenia.
Future research should investigate the human qualitative
impact of lesser grades of neutropenia. We began with this
extreme group to get as clear a picture as possible for this
condition. Furthermore, it is also important to discover
how these difficulties develop as patients progress from a
normal ANC through various grades of neutropenia. For
example, there may be subjectively reported precursors of
grade 4 neutropenia that patients can identify when they
have grade 3 neutropenia. This might be clinically impor-
tant to facilitate identifying those patients who will be at
greater risk for developing severe neutropenia that may
require hospitalization.
Another important limitation of this investigation is the
lack of a comparison group, e.g., patients who were receiv-
ing chemotherapy but who did not experience significant
neutropenia. When one looks at the content of the com-
plaints that patients presented in this investigation, some
of those seem like they would be complaints likely to sur-
face for any patient undergoing chemotherapy. For exam-
ple, a change in the taste perception and nausea are
unlikely to be unique to neutropenia, and may reflect
common complaints for a range of chemotherapy
patients. Considering the major physical complaints of
fatigue and a sense of exhaustion, it would be important
to determine to what extent that complaint was generally
true of chemotherapy patients versus being a complaint
unique to, or especially exacerbated among, chemother-
apy patients who developed significant neutropenia. It
should also be noted that in this prospective study we did
not attempt to correlate additional laboratory values such
as hemoglobin that might be related to fatigue associated
with anemia. Such important factors should be addressed
in more controlled studies where patients with particular
cancers undergoing specific chemotherapy regimens can
be followed prospectively to make the appropriate com-
parison. In addition, experimental investigations where
patients are randomly assigned to receive neutropenia
preventive interventions such as colony stimulating fac-
tors could help to clarify the extent to which such fatigueBMC Nursing 2005, 4:4 http://www.biomedcentral.com/1472-6955/4/4
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is caused by neutropenia as distinct from caused by chem-
otherapy alone.
Neutropenia is certainly a serious medical condition that
many cancer patients will have to face. This has been
known for quite some time. What has been less obvious is
that neutropenia is a medical condition with widespread
cognitive, emotional, and social impacts for patients. In
addition to developing treatment protocols for preventing
and treating neutropenia from a medical standpoint, it is
also important to consider the human experience side
from the point of view of the patient. Both febrile and afe-
brile neutropenia present formidable challenges to chem-
otherapy patients, and their caregivers need to be aware of
these challenges to design treatments that adequately
address them.
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